Strange Ad about A New Hemophilia Product

Sewer rat genes… That’s the science behind a new clotting gel (TT-103MH) made by a company called Thrombotargets Corporation of Spain, a gel which apparently will be able to be used by people with hemophilia. I read about this in an ad in a recent BusinessWeek, as I flew to my meeting last week in New Orleans. Flipping through the pages, the word “hemophilia” caught my eye in a headline. You don’t often see hemophilia anywhere outside of our community, so I immediately read the ad.

The ad declares the FDA has given orphan drug status to this product. And the ad makes many amazing declarations that will raise eyebrows.

The ad is an amazing essay of misinformation. Apparently it is intended to attract investors who want to sink money into something revolutionary and biotechnical–but that doesn’t know its factor VIII from its elbow.

According to the ad, there has been “little scientific innovation in the area of blood coagulation in the past 40 years.” (I guess antihemophilic factor wasn’t anything revolutionary, right?) According to Thrombotargets’ president Dr. Pedreno, “there is no medicine for treating hemorrhages.”  And by using this product, a gel, a hemophilic child can “go play in the park, and if he falls down the hemorrhage can be stopped without having to go to the hospital for a transfusion.” Are they claiming the gel somehow stop internal joint bleeds? Head bleeds? Nothing is said about these bleeds.

And what about topical thrombin products, which have been around a long time and are used for circumcisions, dental work and topical wounds? Maybe I lost something in the Spanish to English translation.

Thrombotargets promises this product will change the lives of those with hemophilia, much like insulin did for diabetics. As we in hemophilia community already know, that was already done, many times over, by antihemophilic factor, then monoclonal AHF, then recombinant AHF–generations 1, 2, 3. If Thrombotargets is going to come to our markets, it had better know its customers. It will be amazed at hemophilia customers–but they don’t like misinformation or grandiose statements. They’ve suffered much too much to be hoodwinked by fast talk and false promises.

Thrombotargets predicts that they can make about $2.1 billion from this product–but I don’t think they will get much of that from the hemophilia community. We’re smart, educated, and dedicated to ever-safer, more convenient and technologically advanced clotting factor. I’ve spent the last 20 years educating hemophilia families, and am proud at how savvy and smart they are when it comes to choices about blood clotting medicine.

Thrombotargets is looking to license the drug with a US pharmaceutical company… let’s hope potential buyers are better at studying their markets than Thrombotargets.


Great Book I Just Read: Mayflower by Nathaniel Philbrick. This is a fascinating and amazing true story about the landing of the Pilgrims, and their hardships in Massachusetts. More than that, it reveals how the native Americans helped them, describes the first true Thanksgiving, and later, how descendants of both the Indians and Pilgrims led the communities to war, which devastated the Indian tribes and shaped the future of New England. Most surprising to learn was the complex, ever-changing relationship between Indians and Pilgrims; there are no bad guys here, just complex people and communities. As a New Englander, I learned so much about how our country was founded, and especially how my state was founded. Anyone interested in American history must read this. Philbrook is a gifted storyteller, and really did his homework. This is a New York Times bestseller and has won many awards. Enjoy it in time for your Thanksgiving!

1 thought on “Strange Ad about A New Hemophilia Product”

Leave a Comment

HemaBlog Archives